Recession-Proof Value Stock: 1 Pharma Stock to Buy Today

Aeterna Zentaris Inc. (TSX:AEZS)(NASDAQ:AEZS) is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests.

| More on:
pharma, vaccine, coronavirus, COVID

Image source: Getty Images

Aeterna Zentaris (TSX:AEZS)(NASDAQ:AEZS) is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The company’s lead product, Macimorelin, is the first and only United States (U.S.) Food and Drug Administration (FDA) and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

Macimorelin is currently marketed in the U.S. under the tradename Macrile through a licence agreement with Novo Nordisk (NYSE:NVO), where Aeterna receives royalties on net sales. According to a commercialization and supply agreement, the company plans to seek regulatory approvals and then commercialize Macimorelin in Israel.

Lucrative royalties

Additionally, upon receipt of pricing and reimbursement approvals, Aeterna expects that Macimorelin will be marketed in Europe and the United Kingdom through a licence agreement with Consilient Health, and Aeterna will receive royalties on net sales and other potential payments. The company is also leveraging the clinical success and compelling safety profile of Macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency, an area of significant unmet need.

Diverse revenue base

The company is actively pursuing business development opportunities for the commercialization of Macimorelin in Asia and the rest of the world, in addition to other non-strategic assets to monetize value. Aeterna’s total revenue for the 12-month period ended December 31, 2020, was $3.7 million as compared with $0.5 million for the same period in 2019, representing an increase of $3.2 million.

The 2020 revenue was comprised of $2.4 million in product sales, $0.9 million in licensing revenue, $0.3 million in supply chain and $0.07 million in royalty income. In 2020, all revenue was earned from Novo Nordisk.

Development of a vaccine against COVID-19

On February 2, 2021, the company announced that it had entered an exclusive option agreement to evaluate a preclinical potential COVID-19 vaccine developed at a university. The vaccine technology developed uses the typhoid fever vaccine, Salmonella Typhi, as a carrier strain and has the potential to be an orally active vaccine against infection with SARS-CoV-2 and development of COVID-19.

Under the option agreement with the university, Aeterna has the right to negotiate an exclusive worldwide licence to develop technology for the prevention of coronavirus diseases, including COVID-19. Management believe that, if it is determined that there is sufficient data to advance into human clinical trials, the development program for this particular COVID-19 vaccine is expected to be abbreviated, because clinical safety data and manufacturing technology is already available for the underlying vaccine strain.

Leveraging platform technology

On March 14, 2021, the company exercised the option in the option agreement and entered a licence agreement with a university. Pursuant to the terms of the university licence agreement, the company has been granted an exclusive, world-wide, licence to certain patents and know-how owned by the university to research, develop, manufacture, and sell a potential COVID-19 vaccine using the university’s bacterial vaccine platform technology.

Recently, the company also announced that it had licensed the exclusive worldwide rights to develop, manufacture, and commercialize targeted, highly specific, autoimmunity modifying proteins, currently in early preclinical development, for the potential treatment of spectrum disorder. This could significantly enhance shareholder value.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

More on Tech Stocks

Lady holding mobile phone and shopping bags
Tech Stocks

The Ultimate Growth Stock to Buy With $1,000 Right Now 

Here's why Shopify (TSX:SHOP) could be the ultimate growth stock long-term investors want to consider at this current point in…

Read more »

Hands shaking over a business deal
Tech Stocks

Meet the Growth Stock I Can’t Stop Buying This Year

Topicus stock (TSXV:TOI) has been a top growth stock this year, with strong finances, a stable acquisition strategy, and more…

Read more »

grow dividends
Tech Stocks

Celestica Stock Is up 44% Since Earnings: What Investors Need to Know

Celestica continues to benefit from strong demand and production efficiencies, yet the stock remains undervalued.

Read more »

healthcare pharma
Tech Stocks

What’s Going on With WELL Health Stock?

WELL stock (TSX:WELL) made strong moves once again, with record earnings and even higher guidance for 2024.

Read more »

A shopper makes purchases from an online store.
Tech Stocks

3 Reasons to Buy Shopify Stock Right Now

Based on these three top reasons, Shopify (TSX:SHOP) stock appears undervalued to buy right now.

Read more »

stock research, analyze data
Tech Stocks

What’s Going on With Lightspeed Stock?

Lightspeed (TSX:LSPD) stock has been climbing once more but is still far from its three-digit share price. So, is it…

Read more »

Target. Stand out from the crowd
Tech Stocks

Missed Out on Nvidia Stock (Again)? Buy Descartes Instead

Nvidia (NASDAQ:NVDA) stock soared yet again after earnings, passing the four-digit mark. But with shares so high, maybe this option…

Read more »

Group of people network together with connected devices
Tech Stocks

This Is the Best Overlooked AI Stock on the TSX Today

This AI stock has been a top growing in the last while, but remains overlooked despite its strong portfolio and…

Read more »